Related Experiment Video
Updated: Aug 18, 2026

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
Published on: September 20, 2020
Percutaneous intervention, surgery, and medical therapy: a perspective from the Duke Databank for Cardiovascular
1Department of Medicine, Duke University Medical Center, Durham, NC 27710.
Insights
Myocardial revascularization surgery offers survival and quality of life benefits for ischemic heart disease patients. The benefits are greater for those with more severe coronary artery disease.
Area of Science:
- Cardiology
- Cardiac Surgery
- Ischemic Heart Disease
Background:
- Symptomatic ischemic heart disease impacts survival and quality of life.
- Myocardial revascularization is a key treatment strategy.
- Advances in medical and interventional therapies necessitate outcome analysis.
Purpose of the Study:
- To analyze contemporary outcomes of myocardial revascularization.
- To correlate anatomic disease severity with treatment benefits.
- To inform rational decision-making in cardiac care.
Main Methods:
- Review of contemporary outcomes data.
- Analysis of survival and quality of life metrics.
- Stratification by anatomic disease severity.
Main Results:
- Myocardial revascularization improves survival and quality of life.
- Benefits are less pronounced in patients with less severe anatomic disease.
- Patients with severe anatomic disease show significant gains from surgical therapy.
Conclusions:
- Myocardial revascularization provides significant benefits for symptomatic ischemic heart disease.
- Treatment decisions should consider anatomic disease severity.
- Ongoing evaluation of outcomes is crucial for optimizing patient care.
Abstract:
Myocardial revascularization improves survival rates and quality of life for patients with symptomatic ischemic heart disease. The less severe the anatomic disease, the smaller the benefit, particularly for survival. Patients with more severe anatomic disease benefit from surgical therapy, in terms of both survival and quality of life. Continuing advances in pharmacological secondary prevention, percutaneous intervention, and surgical treatment mandate continued analysis of contemporary outcomes to provide the best information for rational decision-making.
More Related Videos
Related Concept Videos
Coronary Artery Disease V: Interprofessional Care
Heart Failure VI: Adjunct Therapies
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Atherosclerosis III: Management
Peripheral Artery Disease III: Interprofessional Care

